Brief: Algernon Says Positive Feedback From Health Canada For COVID-19 Treatment Trial
08/04/2020 13:43
April 8 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES POSITIVE FEEDBACK FROM HEALTH CANADA
FOR
IFENPRODIL COVID-19 PHASE 2 HUMAN TRIAL
* ALGERNON PHARMACEUTICALS INC - COMPANY PLANS TO SUBMIT CTA
TO
HEALTH CANADA FOR APPROVAL OF PHASE 2 CLINICAL TRIAL WITHIN NEXT
WEEK
Source text for Eikon: ID:nGNX6gvWTj
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement